FR2740343B1 - Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique - Google Patents

Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique

Info

Publication number
FR2740343B1
FR2740343B1 FR9512635A FR9512635A FR2740343B1 FR 2740343 B1 FR2740343 B1 FR 2740343B1 FR 9512635 A FR9512635 A FR 9512635A FR 9512635 A FR9512635 A FR 9512635A FR 2740343 B1 FR2740343 B1 FR 2740343B1
Authority
FR
France
Prior art keywords
napht
tetrahydropyridine
trifluoromethylphenyl
medicines
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9512635A
Other languages
English (en)
Other versions
FR2740343A1 (fr
Inventor
Patrice Douillet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9512635A priority Critical patent/FR2740343B1/fr
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to SK526-98A priority patent/SK284099B6/sk
Priority to EP96934975A priority patent/EP0866704B1/fr
Priority to NZ320355A priority patent/NZ320355A/xx
Priority to CN96198508A priority patent/CN1104241C/zh
Priority to EE9800132A priority patent/EE04177B1/xx
Priority to PT96934975T priority patent/PT866704E/pt
Priority to DK96934975T priority patent/DK0866704T3/da
Priority to UA98042073A priority patent/UA57004C2/uk
Priority to PCT/FR1996/001674 priority patent/WO1997015304A1/fr
Priority to HU9802945A priority patent/HU222039B1/hu
Priority to AU73084/96A priority patent/AU719342B2/en
Priority to IL12409196A priority patent/IL124091A/xx
Priority to DE69612510T priority patent/DE69612510T2/de
Priority to ES96934975T priority patent/ES2159362T3/es
Priority to US09/051,740 priority patent/US6043251A/en
Priority to BR9611124A priority patent/BR9611124A/pt
Priority to CZ19981296A priority patent/CZ293360B6/cs
Priority to SI9630299T priority patent/SI0866704T1/xx
Priority to KR10-1998-0702997A priority patent/KR100472793B1/ko
Priority to AT96934975T priority patent/ATE200423T1/de
Priority to JP51637097A priority patent/JP3468526B2/ja
Priority to TR1998/00717T priority patent/TR199800717T2/xx
Priority to CA002235747A priority patent/CA2235747C/fr
Publication of FR2740343A1 publication Critical patent/FR2740343A1/fr
Priority to IS4722A priority patent/IS1961B/is
Priority to MXPA/A/1998/003271A priority patent/MXPA98003271A/xx
Priority to NO19981856A priority patent/NO316256B1/no
Application granted granted Critical
Publication of FR2740343B1 publication Critical patent/FR2740343B1/fr
Priority to HK99102262A priority patent/HK1016904A1/xx
Priority to GR20010400880T priority patent/GR3036027T3/el
Priority to CY0200033A priority patent/CY2279B1/xx
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
FR9512635A 1995-10-26 1995-10-26 Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique Expired - Fee Related FR2740343B1 (fr)

Priority Applications (30)

Application Number Priority Date Filing Date Title
FR9512635A FR2740343B1 (fr) 1995-10-26 1995-10-26 Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
SI9630299T SI0866704T1 (en) 1995-10-26 1996-10-25 Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
NZ320355A NZ320355A (en) 1995-10-26 1996-10-25 Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
CN96198508A CN1104241C (zh) 1995-10-26 1996-10-25 1－(2－萘－2－基乙基)－4－(3－三氟甲基苯基)－1,2,3,6－四氢吡啶用于制备治疗肌萎缩性脊髓侧索硬化的药物的用途
CZ19981296A CZ293360B6 (cs) 1995-10-26 1996-10-25 Léčivo pro léčení amyotrofické laterální sklerózy
PT96934975T PT866704E (pt) 1995-10-26 1996-10-25 Uso de 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetra-hidropiridina para a preparacao de medicamentos destinados ao tratamento da esclerose lateral amiotrofica
DK96934975T DK0866704T3 (da) 1995-10-26 1996-10-25 Anvendelse af 1-(2-naphth-2-ylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af amyotrofisk lateralsklerose
EP96934975A EP0866704B1 (fr) 1995-10-26 1996-10-25 Utilisation de la 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
PCT/FR1996/001674 WO1997015304A1 (fr) 1995-10-26 1996-10-25 Utilisation de la 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
KR10-1998-0702997A KR100472793B1 (ko) 1995-10-26 1996-10-25 근위축성측삭경화증치료용약제를제조하기위한1-(2-나프트-2-일에틸)-4-(3-트리플루오로메틸페닐)-1,2,3,6-테트라히드로피리딘의용도
AU73084/96A AU719342B2 (en) 1995-10-26 1996-10-25 Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
IL12409196A IL124091A (en) 1995-10-26 1996-10-25 Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it
DE69612510T DE69612510T2 (de) 1995-10-26 1996-10-25 Verwendung von 1-(2-naphtylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode
ES96934975T ES2159362T3 (es) 1995-10-26 1996-10-25 Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
US09/051,740 US6043251A (en) 1995-10-26 1996-10-25 Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyr idine for preparing drugs for treating amyotrophic lateral sclerosis
BR9611124A BR9611124A (pt) 1995-10-26 1996-10-25 Utilização da 1-(2-naft-2-iletil)-4- (3-trifluorometifenil) -1,2,3,6-tetraidropiridina ou um dos seus sais de adição com ácidos farmaceuticamente aceitáveis composição farmacéutica e método de tratamento da esclerose lateral amiotrófica
SK526-98A SK284099B6 (sk) 1995-10-26 1996-10-25 Použitie 1-(2-naftyl-2-yletyl)-4-(3-trifluórmetylfenyl)-1,2,3,6- tetrahydropyridínu na prípravu liečiva na liečenie amyotrofickej laterálnej sklerózy
UA98042073A UA57004C2 (uk) 1995-10-26 1996-10-25 Лікувальний засіб, що містить 1-(2-нафт-2-ілетил)-4-(3-трифторметилфеніл)-1,2,3,6,-тетрагідропіридин (варіанти), та спосіб лікування бічного аміотрофічного склерозу
HU9802945A HU222039B1 (hu) 1995-10-26 1996-10-25 1-[2-(Naft-2-il)-etil]-4-[3-(trifluor-metil)-fenil]-1,2,3,6-tetrahidro-piridin alkalmazása izomsorvadásos laterális szklerózis kezelésére használható gyógyászati készítmények előállítására
AT96934975T ATE200423T1 (de) 1995-10-26 1996-10-25 Verwendung von 1-(2-naphtylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode
JP51637097A JP3468526B2 (ja) 1995-10-26 1996-10-25 筋萎縮性側索硬化症治療薬調製のための１−（２−ナフタ−２−イルエチル）−４−（３−トリフルオロメチルフェニル）−１，２，３，６−テトラヒドロピリジンの使用
TR1998/00717T TR199800717T2 (xx) 1995-10-26 1996-10-25 Amyotrofik lateral skleroz tedavisine y�nelik ila� haz�rlamak i�in
CA002235747A CA2235747C (fr) 1995-10-26 1996-10-25 Utilisation de la 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
EE9800132A EE04177B1 (et) 1995-10-26 1996-10-25 1-(2-naft-2-üületüül)-4-(3-trifluorometüülfenüül)-1,2,3,6-tetrahüdropüridiini kasutamine ravimite valmistamiseks amüotroofilise lateraalskleroosi raviks
IS4722A IS1961B (is) 1995-10-26 1998-04-21 Notkun 1-(2-naft-2-ýletýl)-4(3-tríflúorómetýlfenýl)-1,2,3,6-tetrahýdrópýridíns til gerðar lyfja tilþess að meðhöndla hliðarstrengjahersli
MXPA/A/1998/003271A MXPA98003271A (en) 1995-10-26 1998-04-24 Use of 1- (2-naft-2-iletil) -4- (3-trifluorometilfenil) -1, 2, 3, 6-tetrahydropiridine for the preparation of drugs for the treatment of lateral sclerosis amiotrof
NO19981856A NO316256B1 (no) 1995-10-26 1998-04-24 Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)- 1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling avamyotrof lateral sklerose
HK99102262A HK1016904A1 (en) 1995-10-26 1999-05-24 Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
GR20010400880T GR3036027T3 (en) 1995-10-26 2001-06-13 Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
CY0200033A CY2279B1 (en) 1995-10-26 2002-05-15 Use of 1- (2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9512635A FR2740343B1 (fr) 1995-10-26 1995-10-26 Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique

Publications (2)

Publication Number Publication Date
FR2740343A1 FR2740343A1 (fr) 1997-04-30
FR2740343B1 true FR2740343B1 (fr) 1999-01-22

Family

ID=9483939

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9512635A Expired - Fee Related FR2740343B1 (fr) 1995-10-26 1995-10-26 Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique

Country Status (1)

Country Link
FR (1) FR2740343B1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2672213B1 (fr) * 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.

Also Published As

Publication number Publication date
FR2740343A1 (fr) 1997-04-30

Similar Documents

Publication Publication Date Title
DZ2405A1 (fr) Utilisation d'antagonistes des récepteurs aux cannabinoïdes centraux pour la préparation de médicaments
ATE284695T1 (de) Oral anzuwendende arzneizusammensetzung enthaltend 2-methyl-thienobenzodiazepin
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
HUP9802945A3 (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
DZ2141A1 (fr) Procédés intermédiares pour la préparation de 1-benzyl-4-(5,6-diméthoxy-1-indanone)-2-yi)méthylpipéridine.
DE69634818D1 (de) Nanopartikeln für die perorale verabreichung von schwerlöslichen arzneimittel
FR2708201B1 (fr) Utilisation de dérivés d'acétamide pour la fabrication de médicaments.
FR2691065B1 (fr) Nouvelles compositions oculaires destinees a la prevention et au traitement de certains troubles de la vision.
FR2712495B1 (fr) Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant.
FR2792835B3 (fr) Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
FR2740343B1 (fr) Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
FR2716623B1 (fr) Utilisation d'un dérivé tricyclique pour l'obtention de médicaments destinés au traitement des troubles mnémo-cognitifs.
FR2792199B3 (fr) Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
FR2714603B1 (fr) Composition dermatologique et son utilisation pour la préparation d'un médicament.
IT1289238B1 (it) Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina
FR2759906B1 (fr) Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques
FR2763847B1 (fr) Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
DE69019693D1 (de) Kieselerdefreies Formenmaterial für den Guss von Titan zu Dentalzwecken.
IT8721945A0 (it) Procedimento per la profumazione di libri, dispositivo per l'attuazione di detto procedimento
FR2675383B1 (fr) Utilisation d'un medicament pour la fabrication d'un medicament destine au traitement des vessies hyperactives ou instables.
FR2732219B1 (fr) Compositions pharmaceutiques pour la prevention et le traitement du paludisme, a base d'un membre de la famille des chondroitine-glycosaminoglycanes
FR2689126B1 (fr) 2-(imino substitué)-thiazolidines, procédé pour les préparer et utilisation pour la préparation des compositions pharmaceutiques.
FR2718027B1 (fr) Produit destiné au traitement et à la prévention des alopécies.
FR2740329B1 (fr) Pilulier portable mensuel pour traitement medicamenteux, hormonal ou autre
FR2744364B1 (fr) Application d'ureidoacetamides a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif

Legal Events

Date Code Title Description
CA Change of address
TP Transmission of property
CD Change of name or company name
ST Notification of lapse

Effective date: 20090630